Drug intelligence / Profile preview

Imatinib ophthalmic

Development stage: Unknown
Lead developer: Avixgen
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Ophthalmic

Overview

AVI-4015 is an ophthalmic formulation of imatinib developed as a small molecule drug for the treatment of dry eye diseases, specifically keratoconjunctivitis sicca (dry eye syndrome) and xerophthalmia. It acts as an antagonist of discoidin domain receptor 1 (DDR1), a tyrosine kinase implicated in ocular surface inflammation. The drug is administered via eye drops and is currently in Phase 2 clinical development. Originally developed by Avixgen, it has also been associated with Enzychem Lifesciences.

Targets

DDR1 (Discoidin domain receptor 1)

Beyond the preview

Go deeper on Imatinib ophthalmic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imatinib ophthalmic.

Explore the full profile